SEC 13F Intelligence

Managers / Q3 2021 · view latest →

FRAZIER MANAGEMENT LLC

CIK 0001032165 · 601 UNION ST, SUITE 2110, SEATTLE, WA, 98101 · 2066217200

Reported Value
$1.2B
Q3 2021
Positions
41
Filings on Record
16
2019–present window
Filed
Nov 12, 2021
original filing

Summary

Frazier Management LLC reported $1.2B in U.S.-listed holdings across 41 positions for Q3 2021.

Its largest position, ARQT, represents 16.1% of the portfolio.

Compared with Q2 2021, the fund opened 8 new positions and exited 1.

Portfolio Metrics

Turnover
+13.8%
vs prior filed quarter
Top-10 Concentration
+67.1%
share of reported value
Largest Position
+16.1%
Arcutis Biotherapeutics
New / Exited
8 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $388MQ4 ’18Q1 ’19: $415MQ2 ’19: $390MQ2 ’19Q3 ’19: $320MQ4 ’19: $596MQ4 ’19Q1 ’20: $882MQ2 ’20: $1.1BQ2 ’20Q3 ’20: $1.1BQ4 ’20: $1.3BQ4 ’20Q1 ’21: $1.2BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $1.2BQ4 ’21: $1.3BQ4 ’21Q2 ’22: $1MQ3 ’22: $0Q3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 80.1%Other: 16.6%ADR: 3.3%
  • Common Stock · 80.1% · $1.0B
  • Other · 16.6% · $207M
  • ADR · 3.3% · $42M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IMAGO BIOSCIENCES INCNEW+2.97M2.97M+$60M$60M
VRDNVIRIDIAN THERAPEUTICS INCNEW+1.51M1.51M+$25M$25M
TYRATYRA BIOSCIENCES INCNEW+1.25M1.25M+$22M$22M
BCYCBICYCLE THERAPEUTICS PLCNEW+442.9K442.9K+$18M$18M
CRNXCRINETICS PHARMACEUTICALS INNEW+851.3K851.3K+$18M$18M
REPLREPLIMUNE GROUP INCNEW+492.0K492.0K+$15M$15M
GRACELL BIOTECHNOLOGIES INCNEW+851.6K851.6K+$12M$12M
KALVISTA PHARMACEUTICALS INCNEW+156.8K156.8K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

41 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM16.12%$201M8.43M
2PHATPHATHOM PHARMACEUTICALS INChistory →COM14.97%$187M5.83M
3MIRMMIRUM PHARMACEUTICALS INChistory →COM5.69%$71M3.57M
4IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM5.28%$66M2.67M
5IMAGO BIOSCIENCES INCCOM4.76%$60M2.97M
6PCVXVAXCYTE INChistory →COM4.69%$59M2.31M
7TREURTRILLIUM THERAPEUTICS INChistory →COM NEW4.40%$55M3.12M
8GRITSTONE BIO INCCOM4.03%$50M4.67M
9PASSAGE BIO INCCOM3.99%$50M5.01M
10KRYSKRYSTAL BIOTECH INChistory →COM3.22%$40M771.3K
11TARSTARSUS PHARMACEUTICALS INChistory →COM2.44%$31M1.42M
12IVERIC BIO INCCOM2.39%$30M1.84M
13SUTRO BIOPHARMA INCCOM2.22%$28M1.47M
14VRDNVIRIDIAN THERAPEUTICS INChistory →COM1.98%$25M1.51M
15ANABANAPTYSBIO INChistory →COM1.95%$24M899.7K
16AUTLAUTOLUS THERAPEUTICS PLChistory →SPON ADS1.85%$23M3.53M
17SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.82%$23M1.19M
18TYRATYRA BIOSCIENCES INChistory →COM1.76%$22M1.25M
19CHINOOK THERAPEUTICS INCCOM1.71%$21M1.67M
20ALPINE IMMUNE SCIENCES INCCOM1.51%$19M1.77M
21BCYCBICYCLE THERAPEUTICS PLChistory →SPONSORED ADS1.47%$18M442.9K
22CRNXCRINETICS PHARMACEUTICALS INhistory →COM1.43%$18M851.3K
23SIERRA ONCOLOGY INCCOM NEW1.41%$18M804.7K
24FRAZIER LIFESCIENCES ACQU COUNIT 12/09/20251.20%$15M1.50M
25REPLREPLIMUNE GROUP INChistory →COM1.17%$15M492.0K
26GRACELL BIOTECHNOLOGIES INCSPONSORED ADS0.95%$12M851.6K
27RGNXREGENXBIO INCCOM0.79%$10M235.8K
28AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.75%$9M951.8K
29MOLECULAR TEMPLATES INCCOM0.74%$9M1.37M
30ACRSACLARIS THERAPEUTICS INCCOM0.59%$7M408.3K
31SRRKSCHOLAR ROCK HLDG CORPCOM0.41%$5M156.0K
32IMVTIMMUNOVANT INCCOM0.41%$5M585.8K
33APTINYX INCCOM0.35%$4M1.88M
34EPIZYME INCCOM0.30%$4M739.4K
35ALLENA PHARMACEUTICALSCOM0.24%$3M3.33M
36ESSA PHARMA INCCOM NEW0.23%$3M358.3K
37KALVISTA PHARMACEUTICALS INCCOM0.22%$3M156.8K
38BLUBELLUS HEALTH INC NEWCOM NEW0.21%$3M433.2K
39GRTXGALERA THERAPEUTICS INCCOM0.16%$2M241.0K
40FREELINE THERAPEUTICS HLDGSSPONSORED ADS0.15%$2M550.0K
41NABRIVA THERAPEUTICS PLCSHS0.04%$507,000425.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$01Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1M1Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022Under review2May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B43Feb 8, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B41Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B34Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.2B35May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.3B35Feb 11, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B31Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B26Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$882M25May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$596M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$320M19Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$390M18Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$415M17May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$388M17Feb 11, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.